DBV Technologies is the only company in the world whose products are designed to epicutaneously deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food allergies or allergy diagnosis. DBV Technologies is listed on the EuroNext [DBV] and is a French company focused on the development of innovative products for the diagnosis and treatment of food allergies.